The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 17th 2025
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Chemoimmunotherapy Assures Better Outcomes in Ovarian Cancer
June 15th 2016According to research published in the journal Clinical Cancer Research, immunotherapy right after chemotherapy can piggy back on the immune modifications caused by the chemotherapy, to improve response to treatment in ovarian cancer.
Read More
What We're Reading: Opioids Cause More Fatalities Than Overdose Deaths
June 15th 2016What we're reading, June 15, 2016: opioids also linked to heart-related deaths and fatalities other than overdoses; judge overrules Federal Trade Commission's efforts to block merger of Advocate Health Care and NorthShore University HealthSystem in Illinois; and using social media to monitor patients outside of the healthcare setting.
Read More
A Smarter Screening Strategy for Prostate Cancer Can Predict Mortality
June 14th 2016A collaborative effort by urologists and public health specialists from various healthcare systems around the country has found that PSA levels measured in midlife (45 to 59 years of age) are a strong predictor of future lethal prostate cancer.
Read More
Adjuvant Chemotherapy Can Improve Survival in Early Stage NSCLC
June 14th 2016A new study, published in the Journal of Thoracic Oncology, has found that chemotherapy administered in patients with stage I disease, following a complete resection, can have a significant impact on their median 5-year overall survival.
Read More
What We're Reading: CMS May Require Medicare Hospitals Follow New Antibiotic Controls
June 14th 2016What we're reading, June 14, 2016: CMS has proposed requiring Medicare hospitals follow new antibiotic controls; New York poised to expand access to breast cancer screening; and clinical trials are seeing more success.
Read More
What We're Reading: WHO Recommends Delaying Pregnancy in Zika-Infected Areas
June 13th 2016What we're reading, June 13, 2016: the World Health Organization is recommending women in Zika-infected areas delay pregnancy; one FDA regulator feels too many drug makers are chasing the same treatments in cancer care; and risky behaviors among American teenagers are down.
Read More
Survey Finds Family Physicians Divided on Recommending LDCT Screening
June 13th 2016A survey conducted among members of the South Carolina Academy of Family Physicians found that although most family physicians reported that they discussed low-dose computed tomography screening (LDCT) with their patients, referrals were low
Read More
Dr Aimee Tharaldson Expects the Biosimilar Approval Process to Pick Up Speed
June 10th 2016The process for approving biosimilars has been moving slowly, but Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, foresees them as having the potential to lower costs for the industry and hopes the approval process will pick up speed.
Watch
Lack of Palliative, Hospice Care Seen Among Veterans Dying of Cancer
June 9th 2016Only half of US veterans who died from cancer received palliative care, while the use of hospice depended upon the care environment. Overall, there was a gap between the percentage of patients who received palliative care and recommended use.
Read More
The field of measurement in Mycosis Fungoides/Sézary syndrome type cutaneous T-cell lymphoma lacked a specific quality-of-life measure to describe patient experience or guide treatment decisions. Using an online platform with an engaged patient community, we developed and psychometrically validated a new measure in just under a year.
Read More
German-Australian AML Study Group Identifies 11 Classes of AML
June 9th 2016The German-Australian AML Study Group, one of the largest global groups evaluating treatments for acute myeloid leukemia (AML), has published results in the New England Journal of Medicine that now classifies AML into 11 classes based on the harbored genetic mutations.
Read More
ASCO Study Finds Daratumumab Economical Over Other Novel MM Agents
June 8th 2016A poster presented at the annual meeting of the American Society of Clinical Oncology (ASCO) found that the cost per median month of survival for daratumumab was lower compared with 2 other novel treatments in multiple myeloma.
Read More
A $67 Million Fine for False Claims on Erlotinib
June 8th 2016The Department of Justice has announced that Genentech and OSI Pharmaceuticals “will pay $67 million to resolve False Claim Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer.”
Read More
Dr Kelly Clark Discusses Challenges of Accessing Opioid Addiction Treatment
June 8th 2016With only 3 medications FDA-approved to treat opioid addiction, patient access to these treatment options can be difficult, and each medication presents its own challenges, said Kelly J. Clark, MD, MBA, president elect of the American Society of Addiction Medicine.
Watch
The Value of a 21-Gene Test in Early-Stage Breast Cancer
June 7th 2016Can the Oncotype DX Breast Cancer Assay impact recommendation and receipt of chemotherapy in early stage breast cancer? Does the test also improve patient experience? These were some of the questions asked by researchers at the University of Michigan, and the results presented during the annual meeting of the American Society of Clinical Oncology.
Read More
What We're Reading: Opioid Restrictions Hurt Those Who Need the Drugs Most
June 7th 2016What we're reading, June 7, 2016: opioid restrictions disproportionately affect older patients with chronic pain; Genentech and OSI Pharmaceuticals settle Tarceva lawsuit; and trouble raising Zika virus funds.
Read More